Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.59 |
| ▸ | F13A1 | P00488 | 8/20 | 0.59 |
| ▸ | TGM1 | P22735 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738625 | 0.89 | TGM2 (0.56) | TGM2F13A1TGM1SMN1; SMN2STS | |
| SCHEMBL392870 | 0.88 | KMT2A (0.64) | TGM2F13A1TGM1SMN1; SMN2STS | |
| SCHEMBL5253160 | 0.87 | POLB (0.70) | TGM2F13A1TGM1STSMEN1 | |
| SCHEMBL5202414 | 0.85 | STS (0.57) | TGM2F13A1TGM1STSTGM3 | |
| SCHEMBL12867436 | 0.85 | PKM (0.55) | TGM2F13A1TGM1SMN1; SMN2STS | |
| SCHEMBL4274049 | 0.84 | STS (0.60) | TGM2F13A1TGM1STSTGM3 | |
| SCHEMBL18702064 | 0.83 | KMT2A (0.56) | SMN1; SMN2MEN1KMT2APOLBRAB9A | |
| SCHEMBL18410584 | 0.83 | TGM2 (0.65) | TGM2F13A1TGM1SMN1; SMN2MEN1 | |
| SCHEMBL6790392 | 0.82 | PKM (0.65) | TGM2F13A1TGM1SMN1; SMN2MEN1 | |
| SCHEMBL29060789 | 0.82 | MAPT (0.73) | TGM2F13A1TGM1SMN1; SMN2STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | TGM2 2164/4885F13A1 3898/4885TGM1 2610/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | TGM2 2399/4885F13A1 3856/4885TGM1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.